D'Amato E, Tammaro P, Craig T J, Tosi A, Giorgetti R, Lorini R, Ashcroft F M
Department of Paediatrics, University of Genoa, IRCCS G. Gaslini, Largo Gaslini, Genoa, Italy.
Diabet Med. 2008 Jun;25(6):651-6. doi: 10.1111/j.1464-5491.2008.02443.x.
Heterozygous activating mutations in KCNJ11, which encodes the Kir6.2 subunit of the pancreatic ATP-sensitive potassium (K(ATP)) channel, cause both permanent and transient neonatal diabetes. Identification of KCNJ11 mutations has important therapeutic implications, as many patients can replace insulin injections with sulphonylurea tablets. The aim was to determine if a KCNJ11 mutation was responsible for a dominantly inherited form of diabetes mellitus, showing variability in age at diagnosis, in an Italian family.
We sequenced KCNJ11 in members of a three-generation family with variable phenotypes of dominantly inherited diabetes mellitus. One had transient early-onset diabetes, one had impaired glucose tolerance during the second pregnancy, and two had young-onset diabetes. None of the subjects showed permanent neonatal diabetes or neurological symptoms.
A novel heterozygous mutation (c. 679C-->G and c. 680A-->T) was identified, resulting in a GAG-->CTG (E227L) substitution in KCNJ11. Functional studies of recombinant heterozygous K(ATP) channels revealed a small reduction in channel inhibition by ATP (IC(50) of 15 micromol/l and 38 micromol/l for wild-type and heterozygous channels, respectively) and an increase in the resting K(ATP) current. This would be expected to impair insulin secretion. The results are in agreement with the mild phenotype of the patients.
Our results broaden the spectrum of diabetes phenotypes resulting from KCNJ11 mutations. They indicate testing for KCNJ11 mutations should be considered not only for neonatal diabetes but also for other forms of dominantly inherited diabetes with later onset, especially where these are associated with a low body mass index and low birth weight.
KCNJ11基因发生杂合激活突变,该基因编码胰腺ATP敏感性钾(K(ATP))通道的Kir6.2亚基,可导致永久性和暂时性新生儿糖尿病。鉴定KCNJ11突变具有重要的治疗意义,因为许多患者可用磺脲类片剂替代胰岛素注射。目的是确定在一个意大利家庭中,KCNJ11突变是否是一种显性遗传形式的糖尿病的病因,该糖尿病在诊断年龄上具有变异性。
我们对一个三代家庭中患有显性遗传糖尿病且具有可变表型的成员进行了KCNJ11基因测序。其中一人患有短暂性早发糖尿病,一人在第二次怀孕时糖耐量受损,两人患有早发糖尿病。所有受试者均未表现出永久性新生儿糖尿病或神经症状。
鉴定出一种新的杂合突变(c. 679C→G和c. 680A→T),导致KCNJ11基因发生GAG→CTG(E227L)替代。对重组杂合K(ATP)通道的功能研究表明,ATP对通道的抑制作用略有降低(野生型和杂合通道的IC(50)分别为15 μmol/l和38 μmol/l),静息K(ATP)电流增加。这预计会损害胰岛素分泌。结果与患者的轻度表型一致。
我们的结果拓宽了由KCNJ11突变导致的糖尿病表型谱。它们表明,不仅对于新生儿糖尿病,而且对于其他晚发型显性遗传糖尿病形式,尤其是那些与低体重指数和低出生体重相关的糖尿病,都应考虑检测KCNJ11突变。